Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety Study of Rotarix TM in Taiwanese Infants Who Received Hepatitis B Immunoglobulin After Birth.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who the investigator believes that parent(s)/Legally Acceptable Representative(s) can and will comply with the requirements of the protocol.~* A male or female between, and including, 6 and 12 weeks of age at the time of the first vaccination.~* Written informed consent obtained from the parent(s)/Legally Acceptable Representative(s) of the subject.~* Healthy subjects as established by medical history and clinical examination before entering into the study.~* Infants who have received a previous dose of hepatitis B immunoglobulin after birth.~Exclusion Criteria:~* Child in care.~* Use of any investigational or non-registered product other than the study vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period.~* Chronic administration of immunosuppressants or other immune-modifying drugs with the exception of Hepatitis B immunoglobulin since birth. Child is unlikely to remain in the study area for the duration of the study.~* Planned administration/administration of a vaccine not foreseen by the study protocol within 30 days of the first dose of vaccine.~* Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.~* Previous vaccination against rotavirus.~* Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.~* Family history of congenital or hereditary immunodeficiency.~* History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine.~* Major congenital defects or serious chronic illness.~* Acute disease and/or fever at the time of enrolment.~* Administration of immunoglobulins (with the exception of HBIG) and/or any blood products since birth or planned administration during the study period.~* Gastroenteritis within 7 days preceding the study vaccine administration.~* Previous confirmed occurrence of Rotavirus gastroenteritis.

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 12 Weeks
- Healthy Volunteers: t

Study Arms:
- Rotarix Group (Type: EXPERIMENTAL): subjects received 2 oral doses of Rotarix™ vaccine at 2 and 4 months of age.

Based on this trial design, predict the completion outcome and termination type (if applicable).